Corbus Pharmaceuticals (CRBP) Guggenheim Inaugural Global Healthcare Innovation Conference summary

Pipeline overview and strategy

• Relaunched with a new pipeline featuring two oncology assets and one obesity asset, all selected for affordability and high success potential.

• Each asset is a fast follower to larger companies' programs, allowing lessons to be learned from competitors' experiences.

• Focus is on differentiation and potential best-in-class status, especially by leveraging data from those ahead in development.

• Assets are advanced to the clinic with the intention of eventual partnerships for late-stage development and commercialization.

• R&D synergies stem from rapid adaptation to competitor learnings and efficient clinical progression.

Obesity program (CRB-913)

• CRB-913 is a CB1 inverse agonist with 15x less brain penetration than leading competitor monlunabant, aiming to reduce neuropsychiatric side effects.

• Both CRB-913 and monlunabant are expected to have key dose response data in 2026, potentially allowing CRB-913 to match or surpass the competitor.

• Preclinical data suggest a strong dose response and reduced risk of severe neuropsychiatric events due to peripheral restriction.

• Central activity is still necessary for efficacy, but CRB-913 aims to optimize the balance between brain and peripheral effects.

• Phase I trials will begin in early 2025, with a focus on safety, dose response, and benchmarking against existing data.

Oncology program (CRB-701, Nectin-4 ADC)

• CRB-701 targets Nectin-4 with a next-generation ADC, featuring site-specific conjugation and a precise drug-to-antibody ratio for improved safety and efficacy.

• The construct is designed for better tolerability and longer duration on therapy compared to Padcev, with a focus on non-bladder cancer indications.

• Key competitors include Pfizer, Bicycle Therapeutics, and Mabwell, with Corbus targeting tumor types where competitors are less active, such as cervical cancer.

• U.S. and European bridging studies will compare safety and efficacy to Chinese data, with results expected in Q1 2025.

• Project Optimus cohorts will further explore monotherapy and combination regimens across multiple tumor types.